Changchun High-Tech subsidiary's trivalent flu vaccine trial approved

Changchun High & New Technology Industry Group announced its subsidiary, Changchun BCHT Biotechnology Co., Ltd. ("BCHT Bio"), received approval from the National Medical Products Administration for the clinical trial of its trivalent influenza virus split vaccine (BK-01 adjuvant). The approval, granted on October 13, 2025, allows BCHT Bio to proceed with clinical trials for the vaccine, intended to prevent seasonal influenza. This adds to BCHT Bio’s adjuvant influenza vaccine portfolio, which also includes a quadrivalent version approved in June 2025.

The trivalent influenza vaccine, targeting individuals aged 60 and above, is designed to stimulate a stronger immune response and provide enhanced protection against influenza, particularly for the elderly. The World Health Organization has identified vaccination as the most effective method for preventing influenza, which can lead to 3-5m severe cases and 290,000-650,000 deaths annually. The removal of the B/Yamagata lineage from global vaccine recommendations in 2024 further highlights the relevance of trivalent vaccines.

While this approval marks progress, the company cautions that subsequent clinical trials and eventual commercialization of the trivalent influenza virus split vaccine (BK-01 adjuvant) are subject to uncertainties. The approval itself is not expected to significantly impact the company's recent financial performance.